Receptos Inc. (Nasdaq: RCPT) reported positive results from a Phase 2 study of its relapsing multiple sclerosis treatment RPC1063 sending the stock price soaring $10.74 to close at $39.94.
Receptos reports positive results
June 10, 2014 at 18:52 PM EDT
